Corning Jerry Pharmaceutical-B (09966.HK) issued an announcement that on October 27, 2022, the company has obtained the approval of the new drug clinical trial (IND) of the Ia/Ib phase clinical trial of the Ia/Ib phase clinical trial. This study will evaluate the safety and tolerance of JSKN003 in patients with advanced malignant solid tumors in China, and determine the maximum tolerated dose (MTD) and/or the recommended dose of Phase II (RP2D) of JSKN003 during the treatment of advanced malignant solid tumors.
As of the close of October 27, 2022, Corning Jerry Pharmaceutical-B (09966.HK) closed at 6.0 yuan, down 2.44%, a turnover rate of 0.64%, a trading volume of 5.967 million shares, and a trading volume of of 36.695 million yuan. Investment banks mainly use increase in holdings. In the past 90 days, two investment banks have given increase in holdings. The target average price in the past 90 days is 16.38. Northeast Securities The latest research report gave Corning Jerry Pharmaceutical-B an increase rating.
Institutional rating details are shown in the table below:
Corning Jerry Pharmaceutical-B Hong Kong stock market value is HK$5.776 billion, ranking 19th in the biologics II industry. The main indicators are shown in the table below:
or above content is compiled by Securities Star based on public information and has nothing to do with the position of this site. Securities Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.
